- Home
- EWTX vs SRRK Comparison
EWTX vs SRRK Comparison
Compare EWTX & SRRK Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- EWTX
- SRRK
- Stock Information
- Founded
- EWTX 2017
- SRRK 2012
- Country
- EWTX United States
- SRRK United States
- Employees
- EWTX 117
- SRRK N/A
- Industry
- EWTX Biotechnology: Pharmaceutical Preparations
- SRRK Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- EWTX Health Care
- SRRK Health Care
- Exchange
- EWTX Nasdaq
- SRRK Nasdaq
- Market Cap
- EWTX 1.5B
- SRRK 3.2B
- IPO Year
- EWTX 2021
- SRRK 2018
- Fundamental
- Price
- EWTX $13.01
- SRRK $35.55
- Analyst Decision
- EWTX Buy
- SRRK Strong Buy
- Analyst Count
- EWTX 9
- SRRK 6
- Target Price
- EWTX $39.89
- SRRK $42.17
- AVG Volume (30 Days)
- EWTX 936.5K
- SRRK 1.5M
- Earning Date
- EWTX 08-07-2025
- SRRK 08-07-2025
- Dividend Yield
- EWTX N/A
- SRRK N/A
- EPS Growth
- EWTX N/A
- SRRK N/A
- EPS
- EWTX N/A
- SRRK N/A
- Revenue
- EWTX N/A
- SRRK N/A
- Revenue This Year
- EWTX N/A
- SRRK N/A
- Revenue Next Year
- EWTX N/A
- SRRK $502.60
- P/E Ratio
- EWTX N/A
- SRRK N/A
- Revenue Growth
- EWTX N/A
- SRRK N/A
- 52 Week Low
- EWTX $10.60
- SRRK $6.76
- 52 Week High
- EWTX $38.12
- SRRK $46.98
- Technical
- Relative Strength Index (RSI)
- EWTX 35.24
- SRRK 57.16
- Support Level
- EWTX $12.72
- SRRK $31.63
- Resistance Level
- EWTX $13.84
- SRRK $36.93
- Average True Range (ATR)
- EWTX 0.67
- SRRK 2.08
- MACD
- EWTX -0.18
- SRRK 0.10
- Stochastic Oscillator
- EWTX 24.36
- SRRK 75.97
About EWTX Edgewise Therapeutics Inc.
Edgewise Therapeutics Inc is a clinical-stage biopharmaceutical company. It is focused on the discovery, development, and commercialization of treatments for severe, rare muscle disorders. It is developing orally bioavailable, small molecule therapies for musculoskeletal diseases. The company's product candidates are Sevasemten and EDG-7500. Sevasemten is an orally administered small molecule designed to address the root cause of dystrophinopathies including Duchenne muscular dystrophy (Duchenne) and Becker muscular dystrophy (Becker). The company is currently studying Sevasemten in Phase 2 trials, which are being held in the U.S. and Israel and in certain countries in Europe and Australasia.
About SRRK Scholar Rock Holding Corporation
Scholar Rock Holding Corp is a late-stage biopharmaceutical company focused on discovering, developing, and delivering innovative medicines for treating serious diseases in which signaling by protein growth factors plays a fundamental role. Its pipeline includes Neuromuscular and Obesity, Immuno-oncology, Fibrotic Disease, and Hematology. The group operates and manages its business as a single segment to assess performance and make operating decisions.